Safety Evaluation of the ADAM System

Oligospermia Clinical Trial

Official title:

Open-label, Single Arm, Multi-Centre, Prospective First-in-Human Study to Assess the Safety of the ADAM™ System

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05134428
• Other study ID #: ADM-012
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 20, 2022
• Est. completion date: June 30, 2025

Study information

• Verified date: April 2024
• Source: Contraline, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and feasibility of the ADAM System for implantation into the vas deferens in 60 healthy males at 3 sites. This is a prospective, non-randomized, open label interventional trial.

Description:

There are three cohorts to monitor safety in this study, each cohort will have 15 participants each:

• Cohort 1: The first 5 subjects will be reviewed for safety by a Data Safety Monitoring Board (DSMB) at 30 days post-implantation. The 15 subjects will then be followed up to 24 months or until their semen analyses is ≥ 15 million sperm/mL.

• Cohort 2: An additional 15 subjects will be enrolled and implanted with ADAM after the DSMB Safety Review of the first 5 subjects at 30 days. They will be followed up to 24 months or until or until their semen analyses is ≥ 15 million sperm/mL.

• Cohort 3: An additional 15 subjects will be enrolled and implanted with ADAM after the DSMB Safety Review of the first 5 subjects at 30 days. They will be followed up to 24 months or until or until their semen analyses is ≥ 15 million sperm/mL.

• Cohort 4: An additional 15 subjects will be enrolled and implanted with ADAM after the DSMB Safety Review of the first 5 subjects at 30 days. They will be followed up to 24 months or until or until their semen analyses is ≥ 15 million sperm/mL.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: June 30, 2025
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

1. The subject is male

2. Subject is 25 to 65 years of age

3. Subject has a normal semen analysis (= 15 million sperm/mL, =40% total motility) defined by the WHO Laboratory Manual for the Examination and Processing of Human Semen (5th Edition), based on the average of two semen samples =2 days and =7 days apart

4. Subject is suitable to undergo a vasectomy as a long-term form of contraception

5. Subject is legally competent

6. In the opinion of the Investigator, the subject is willing and able to comply with the protocol, return for all follow-up visits and complete all protocol assessments, which includes providing recurring semen samples

7. Subject agrees to use an alternative method of contraception with any female partner of reproductive age during the course of the study treatment until study exit occurs

8. Subject is willing to accept an unknown risk of conceiving a pregnancy during the duration of the study.

9. The subject has been informed of the nature of the study, agrees to its provisions, and has willingly provided written informed consent, approved by the appropriate Human Research Ethics Committee (HREC) -

Exclusion Criteria:

• Potential subjects will be excluded if ANY of the following criteria apply:

1. Subject is participating in another interventional clinical trial currently or within the past 3 months from the time of screening

2. Subject has history of prior hormonal therapy use (e.g., androgenic steroids, GnRH agonists and antagonists) within the past 6 months

3. Subject on exam has any of the following: vas not present, abnormal scrotum, large varicocele, hydrocele, filariasis or elephantiasis of scrotum, or intrascrotal mass that would make the subject not suitable for the study

4. Subject has allergic reaction to polyethylene glycol (PEG) containing products or has had a prior severe allergic response to injectable or implantable devices

5. Subject has local genital infections such as balanitis, scrotal skin infection, epididymitis, or orchitis, or tender (inflamed) tip of the penis, but may be admitted after resolution of an acute infection

6. Subject has current coagulopathy or other bleeding disorders

7. Subject currently taking or planning to take any type of systemic medication which could affect sperm count or ejaculation (e.g., anabolic steroids, chemotherapy, alpha blocker)

8. Subject had a previous successful or unsuccessful vasectomy or vasectomy reversal

9. Subject has any clinically significant abnormal findings or other findings identified by Investigator that would exclude the subject.

Related Conditions & MeSH terms

• Azoospermia
• Oligospermia

Intervention

Device:
• ADAM System
The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.

Locations

Country	Name	City	State
Australia	AndroUrology	Brisbane	Queensland
Australia	Epworth HealthCare	E. Melbourne	Victoria
Australia	South Coast Urology	Wollongong	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Contraline, Inc

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events	The primary endpoint is the number of all treatment-emergent adverse events	30 Days
Secondary	Serious AEs	Number and percentage of subjects experiencing procedure and device-related serious adverse events at 30 days	30 Days
Secondary	Adverse Events of Interest	Number and percentage of subjects experiencing an adverse event of interest during the study	3 years
Secondary	Azoospermia	Percentage of subjects achieving absolute azoospermia, defined as a zero sperm count, and percentage of subjects achieving virtual azoospermia, defined as a sperm count of =100,000 per mL and 0% motility	3 years